ClinicalTrials.gg
CompletedNCT02963116Updated Mar 9, 2017

A Study to Estimate the Effect of AZD5718 on the Pharmacokinetics (What Does the Body Does to the Drug) of Rosuvastatin to Measure the Relative Bioavailability (the Extent to Which a Drug or Other Substance Becomes Available to the Body) of AZD5718 Oral Suspension vs AZD5718 Immediate Release Tablet

A Phase 1 interventional study of AZD5718 IR tablet and AZD5718 oral suspension in High Risk Coronary Artery Disease, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-09.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing rosuvastatin in Coronary Artery Disease — 2 open to participants now, 5 under way, 1 of them phase 3. rosuvastatin · Coronary Artery Disease.

Enrollment
34th of 34
12 · median 175
Started
2016
the only one that year
Phase 1
2 of 34
none open now
Registered
25th of 34
by date
Lead sponsor
4 of 34
AstraZeneca

Among the 34 studies testing rosuvastatin in Coronary Artery Disease, this one is the 34th largest by enrollment, is the only one that started in 2016, is one of 2 in phase 1, and was the 25th registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

2 of the 34 studies testing rosuvastatin in Coronary Artery Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing rosuvastatin in Coronary Artery Disease, or all of them as a file.
02

Study summary

This study is a randomized, open-label, 5-period, 5-treatment, single-dose, single-center, crossover study to estimate the effect of AZD5718 on the pharmacokinetics (PK) of rosuvastatin, and to assess the relative bioavailability of AZD5718 oral suspension vs AZD5718 immediate release (IR) Tablet Formulation and the Food Effect of AZD5718 in Healthy Volunteers. The study will be performed at a single study center.

Read the detailed description

The study will comprise:

  • A Screening period of maximum 28 days;
  • Five treatment periods during which subjects will be resident from the morning on the day before dosing with the IMP (Day -1) until at least 48 hours after dosing; discharge will be on the morning of Day 3, and
  • A Follow-up Visit within 7 to 10 days after the last administration of the IMPs.
  • There will be a minimum of a 7 days washout between each treatment period.

Each subject will receive 5 treatments. The following treatments will be given:

  • Treatment A: 10 mg rosuvastatin tablet alone (fasting state)
  • Treatment B: 10 mg rosuvastatin tablet + 200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fasting state)
  • Treatment C: 200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fasting state)
  • Treatment D: 200 mg of AZD5718 oral suspension 50 mg/mL (fasting state)
  • Treatment E: 200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fed state)

Each subject will be involved in the study for approximately 8 weeks.

03

Conditions studied

  • High Risk Coronary Artery Disease

Keywords

  • Pharmacokinetics (PK)
  • Bioavailability (BA)
  • Safety
  • Tolerability
  • Healthy Volunteers
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For inclusion in the study, subjects should fulfill the following criteria:

  1. Provision of signed and dated, written prior to any study specific procedures.
  2. Healthy male and/or female subjects (of non ) aged 18 to 50 years (inclusive) with suitable veins for cannulation or repeated venipuncture.
  3. Females must have a negative pregnancy test at the Screening Visit and on admission to the unit, must not be lactating and must be of non-childbearing potential, confirmed at the Screening Visit by fulfilling one of the following criteria 3.1. defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and follicle stimulating hormone levels in the postmenopausal range.

    3.2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral ophorectomy or bilateral salpingectomy but excluding bilateral tubal ligation.

  4. Have a (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg, inclusive.
  5. Provision of signed, written and dated informed consent for optional genetic/biomarker research. If a subject declines to participate in the genetic component of the study, there will be no penalty or loss of benefit to the subject. The subject will not be excluded from other aspects of the study.

Exclusion criteria

Exclusion Criteria:

Subjects will not enter the study if any of the following exclusion criteria are fulfilled:

  1. History of any disease or disorder which, in the opinion of the PI, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
  2. History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  3. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP.
  4. Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results, at the Screening Visit and/or admission to the study unit as judged by the PI including: - Aminotransferase () > (ULN); - Aspartate aminotransferase (AST) > ULN; - Total (TBL) > ULN; and - Gamma glutamyl transpeptidase (GGT) > ULN.
  5. Any clinically significant abnormal findings in vital signs at the Screening Visit and/or admission to the study unit, as judged by the PI defined as any of the following: - Systolic BP (SBP) \< 90 mmHg or ≥ 140 mmHg; - Diastolic BP (DBP) \< 50 mmHg or ≥ 90 mmHg; and - Pulse \< 45 or > 85 beats per minute (bpm).
  6. Any clinically significant abnormalities (at the Screening Visit and admission) in rhythm, conduction or morphology of the resting and any clinically significant abnormalities in the 12-lead ECG, as considered by the investigator that may interfere with the interpretation of changes, including abnormal ST-T-wave morphology, particularly in the protocol defined primary lead or left ventricular hypertrophy.
  7. Any positive result on screening for serum surface antigen, antibody, and (HIV) antibody.
  8. Subjects with myopathy.
  9. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study. The period of exclusion begins 3 months after the final dose or 1 month after the last visit whichever is the longest. Note: subjects consented and screened, but not randomized in this study or a previous phase I study, are not excluded.
  10. Plasma donation within 1 month of the Screening Visit or any blood donation/loss more than 500 mL during the 3 months prior to the Screening Visit.
  11. History of severe allergy/ or ongoing allergy/hypersensitivity, as judged by the PI or history of hypersensitivity to drugs with a similar chemical structure or class to AZD5718 and/or rosuvastatin.
  12. Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the 3 months prior to the Screening Visit.
  13. Positive screen for drugs of abuse or cotinine at the Screening Visit or on each admission to the study center or positive screen for alcohol on each admission to the study center.
  14. Excessive intake of caffeine containing drinks or food (e.g., coffee, tea, chocolate), as judged by the investigator.
  15. Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.
  16. Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half-life. Note: Hormonal replacement therapy is not allowed for females.
  17. Known or suspected history of alcohol or drug abuse or excessive intake of alcohol as judged by the PI.
  18. Involvement of any AstraZeneca, PAREXEL or study site employee or their close relatives. 19. Subjects who have previously received AZD5718.
  1. Judgment by the PI that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.
  1. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order In addition, the following is considered a criterion for the exclusion from the optional genetic component of the study: 22. Previous bone marrow transplant. 23. Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection or previous bone marrow transplant.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Treatment A

    10 mg rosuvastatin tablet alone (fasting state)

    Drug: Rosuvastatin tablet

  • Experimental
    Treatment B

    10 mg rosuvastatin tablet + 200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fasting state)

    Drug: AZD5718 IR tablet · Drug: Rosuvastatin tablet

  • Experimental
    Treatment C

    200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fasting state)

    Drug: AZD5718 IR tablet

  • Experimental
    Treatment D

    200 mg of AZD5718 oral suspension 50 mg/mL (fasting state)

    Drug: AZD5718 oral suspension

  • Experimental
    Treatment E

    200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fed state)

    Drug: AZD5718 IR tablet

06

What researchers measure

Primary outcomes

  1. Area under plasma concentration-time curve from time zero to infinity (AUC) of Rosuvastatin

    Assessment of AUC of rosuvastatin when administered alone and in combination with AZD5718 in healthy volunteers.

    Time frame: Pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 h post-dose

  2. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-last)] of Rosuvastatin

    Assessment of AUC(0-last) of rosuvastatin when administered alone and in combination with AZD5718 in healthy volunteers.

    Time frame: Pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 h post-dose

  3. Maximum observed plasma concentration (Cmax) of Rosuvastatin

    Assessment of Cmax of rosuvastatin when administered alone and in combination with AZD5718 in healthy volunteers.

    Time frame: Pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 h post-dose

Secondary outcomes

  1. Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½) of Rosuvastatin -

    Assessment of t½ of rosuvastatin.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 h post-dose. (Only Treatment A and B)

  2. Time to reach maximum observed plasma concentration (tmax) of rosuvastatin

    Assessment of tmax of rosuvastatin.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 h post-dose. (Only Treatment A and B)

  3. AUC of AZD5718

    Assessment of AUC of AZD5718.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 h post-dose (Only Treatment B, C, D, and E)

  4. AUC(0-last) of AZD5718

    Assessment of AUC(0-last) of AZD5718.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 h post-dose (Only Treatment B, C, D, and E)

  5. Cmax of AZD5718

    Assessment of Cmax of AZD5718.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 h post-dose (Only Treatment B, C, D, and E)

  6. tmax of AZD5718

    Assessment of tmax of AZD5718.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 h post-dose (Only Treatment B, C, D, and E)

  7. t½ of AZD5718

    Assessment of t½ of AZD5718.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 h post-dose (Only Treatment B, C, D, and E)

  8. Apparent total body clearance of drug from plasma after extravascular administration (CL/F) of AZD5718

    Assessment of CL/F of AZD5718.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 h post-dose (Only Treatment B, C, D, and E)

  9. Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) of AZD5718

    Assessment of Vz/F of AZD5718.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 h post-dose (Only Treatment B, C, D, and E)

  10. Adverse events (AEs)

    Assessment of the safety in terms of the incidences of the AEs.

    Time frame: Screening, Day -1 and Days 1 to 3 (treatment periods 1 to 5) and follow up visit (7-10 days post final dose)

  11. Vital signs (systolic and diastolic blood pressure, pulse rate and body temperature)

    Assessment of the safety in terms of the Vital signs (systolic and diastolic blood pressure, pulse rate).

    Time frame: Screening, Day -1, Pre-dose, 48 h post-dose and Follow-up visit (7-10 days post final dose)

  12. Electrocardiogram (ECG)

    Assessment of the safety in terms of the ECG.

    Time frame: Screening, Day -1, Pre-dose, 48 h post-dose and Follow-up visit (7-10 days post final dose)

  13. Physical examination

    Assessment of the safety in terms of the physical examination.

    Time frame: Screening, Day -1 (brief), 48 h (brief) post-dose

  14. Laboratory assessments (hematology, clinical chemistry and urinalysis).

    Assessment of the safety in terms of the Clinical laboratory assessments (hematology, clinical chemistry and urinalysis).

    Time frame: Screening, Day -1 (only limited clinical laboratory evaluations will be performed), Pre-dose, 48 h post-dose and Follow-up Visit (7-10 days post final dose)

07

Study locations

1 site
  • Research Site
    London, United Kingdom
08

References and documents

Publications

  • Ericsson H, Nelander K, Heijer M, Kjaer M, Lindstedt EL, Albayaty M, Forte P, Lagerstrom-Fermer M, Skrtic S. Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability. Clin Pharmacol Drug Dev. 2020 Apr;9(3):411-421. doi: 10.1002/cpdd.756. Epub 2019 Dec 2. PubMed 31793171 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Mar 2017, 2 months.

Of 34 phase 1 interventional studies under Coronary Artery Disease, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2016
First posted
Nov 15, 2016
StartActual
Dec 20, 2016
Primary completionActual
Mar 1, 2017
CompletionActual
Mar 1, 2017
Last update
Mar 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02963116
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 15, 2016
Start date
Dec 20, 2016
Primary completion
Mar 1, 2017
Completion
Mar 1, 2017
Last update
Mar 9, 2017

Study contacts

Dr. Muna Albayaty, MBChB, MSc, MFPM
principal investigator · PAREXEL Early Phase Clinical Unit London

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AZD5718 · Rosuvastatin

Start the discussion